Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer that progressed after aromatase inhibitor therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Faslodex (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-08-13